サイクリン依存性キナーゼ（CDK）4/6阻害剤の世界市場レポート 2024

サイクリン依存性キナーゼ（CDK）4/6阻害剤の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には19.5%の年間複合成長率（CAGR）で251億7,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、CDK 4/6阻害剤の適応症の拡大、新しいパイプライン分子の出現、市場競争と価格変動の影響、個別化医療アプローチの採用、および世界のヘルスケアインフラの改善。予測期間中に予想される主な動向としては、バイオマーカー同定の進歩、経口CDK 4/6阻害剤の台頭、他のがん種におけるCDK 4/6阻害剤の探索、耐性メカニズムの克服に焦点を当てた取り組み、臨床試験の増加、新たなCDK 4/6阻害剤が挙げられます。

乳がんの罹患率の予想される増加により、サイクリン依存性キナーゼ（CDK）4/6阻害剤市場の成長が促進される見込みです。乳がんは乳房細胞から発生するため、CDK4/6阻害剤などの標的療法の需要が高まっており、特定の種類の乳がんに対処し、増加する病気の蔓延の管理に貢献しています。 2023年1月に米国がん協会が報告したように、乳がん症例数は2021年の28万4,200人から2023年には30万590人に急増し、5.76%の大幅な増加を記録しました。したがって、乳がんの有病率の上昇は、サイクリン依存性キナーゼ（CDK）4/6阻害剤市場の成長を推進する極めて重要な推進力となると予測されています。

乳がん治療の研究開発への投資の増加により、サイクリン依存性キナーゼ（CDK）4/6阻害剤市場が大幅に拡大すると予想されます。乳がん治療における資金の増加により、CDK4/6阻害薬の革新と拡大が促進され、その有効性が強化され、その用途が拡大し、それによって市場の拡大が促進されます。たとえば、米国に本拠を置く評判の高い乳がん団体であるスーザンG.コーメンは、2022年 6月に、米国の26の著名な学術医療機関における48件の新しい調査イニシアチブのスポンサーとして2,170万米ドルを割り当てました。これらの取り組みは、特に進行性の乳がんに取り組んでいる人、または再発や転移に直面している人にとって、患者の転帰を向上させることを目的としています。したがって、乳がん治療のための研究開発への投資の拡大が、サイクリン依存性キナーゼ（CDK）4/6阻害剤市場の成長を推進する重要な要因として浮上しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場、薬剤タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• パルボシクリブ（イブランス）
• リボシクリブ（キスカリ）
• アベルマシクリブ（ヴェルゼニオ）
• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場、患者別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 閉経前
• 閉経後
• その他の患者
• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• クリニック
• 研究
• 小売薬局

第7章 地域および国の分析

• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• サイクリン依存性キナーゼ（CDK）4/6阻害剤市場の競合情勢
• サイクリン依存性キナーゼ（CDK）4/6阻害剤市場の企業プロファイル
  • Pfizer Inc.
  • Merck &Co. Inc.
  • Novartis AG
  • Bristol Myers Squibb Company
  • AstraZeneca PLC

第31章 その他の大手および革新的な企業

• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Gilead Sciences, Inc
• Incyte Corporation
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Dr. Reddy's Laboratories Ltd
• Piramal Group
• Hanmi Pharm Co. Ltd.
• Incepta Pharmaceuticals Ltd
• Beacon Pharmaceuticals PLC
• Bluepharma
• Astex Pharmaceuticals
• Arvinas Inc
• G1 Therapeutics Inc.
• Carisma Therapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Cyclin-dependent kinase (CDK) 4/6 inhibitor drugs are a class of targeted therapy medications employed in the treatment of specific types of hormone receptor-positive, HER2-negative breast cancer. These drugs focus on inhibiting enzymes known as CDK4 and CDK6, disrupting signals that stimulate the proliferation of malignant cells.

The primary CDK 4/6 inhibitor drugs include palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Palbociclib, for instance, is a targeted therapy medication designed for treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is often utilized in combination with endocrine therapy, offering an effective treatment option for patients with advanced or metastatic breast cancer. These drugs cater to various patient groups, such as premenopausal, postmenopausal, and others. The end users encompass hospitals, clinics, research laboratories, and retail pharmacies.

The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market research report is one of a series of new reports from The Business Research Company that provides cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market statistics, including cyclin-dependent kinase (CDK) 4/6 inhibitor drugs industry global market size, regional shares, competitors with a cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market share, detailed cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs industry. This cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market size has grown exponentially in recent years. It will grow from $10.18 billion in 2023 to $12.35 billion in 2024 at a compound annual growth rate (CAGR) of 21.3%. The growth observed in the historic period can be attributed to several factors, including the increasing incidence of cancer, clinical success stories showcasing the efficacy of CDK 4/6 inhibitors, a growing aging population, and heightened awareness leading to early diagnosis. These factors collectively contributed to the historical expansion of the use of CDK 4/6 inhibitor drugs in breast cancer treatment.

The cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market size is expected to see rapid growth in the next few years. It will grow to $25.17 billion in 2028 at a compound annual growth rate (CAGR) of 19.5%. The anticipated growth in the forecast period can be attributed to various factors, including the expansion of indications for CDK 4/6 inhibitors, the emergence of new pipeline molecules, the impact of market competition and pricing dynamics, the adoption of personalized medicine approaches, and improvements in global healthcare infrastructure. Major trends expected in the forecast period include advancements in biomarker identification, the rise of oral CDK 4/6 inhibitors, the exploration of CDK 4/6 inhibitors in other cancer types, efforts focused on overcoming resistance mechanisms, and an increase in clinical trials exploring novel CDK 4/6 inhibitors.

The anticipated increase in the prevalence of breast cancer is poised to drive the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market. Breast cancer, originating in breast cells, prompts the demand for targeted therapies such as CDK4/6 inhibitors, addressing specific types of breast cancer and contributing to managing the escalating prevalence of the disease. As reported by the American Cancer Society in January 2023, breast cancer cases surged from 284,200 in 2021 to 300,590 in 2023, marking a significant increase of 5.76%. Consequently, the rising prevalence of breast cancer is forecasted to be a pivotal driver propelling growth within the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

The augmented investment in research and development endeavors for breast cancer treatment is expected to significantly boost the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market. The increased funding in breast cancer treatment facilitates the innovation and expansion of CDK4/6 inhibitor drugs, enhancing their efficacy and broadening their applications, thereby fostering market expansion. For instance, Susan G. Komen, a reputable US-based breast cancer organization, allocated $21.7 million in June 2022 to sponsor 48 novel research initiatives at 26 esteemed academic medical institutions across the United States. These initiatives aim to enhance patient outcomes, particularly for individuals grappling with aggressive forms of breast cancer or facing recurrence or metastasis. Hence, the amplified investment in research and development for breast cancer treatment emerges as a key factor driving the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

The distinctive array of side effects associated with cyclin-dependent kinase (CDK) 4/6 inhibitor drugs presents a challenge that could potentially impede the market's growth in the forecast period. Among these side effects, neutropenia stands out, marked by a decrease in white blood cells that elevates the risk of infections. This condition is transient and dosage-dependent, typically resolving when the drug dose is adjusted or temporarily halted. According to the National Library of Medicine in June 2023, the most prevalent side effect of CDK 4/6 inhibitors was neutropenia, with rates of occurrence at 80% for palbociclib, 75% for ribociclib, and 41% for abemaciclib. Consequently, the incidence of these side effects poses a hindrance to the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

Major companies operating within the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market are directing their efforts toward the development of advanced therapies, notably combination therapies, aiming to further enhance the treatment landscape for patients, address unmet medical needs, and optimize patient outcomes. Combination therapies involve the simultaneous use of two or more diverse treatment modalities or drugs, aiming to augment the effectiveness of medical interventions. For instance, in October 2021, Eli Lilly and Company, a leading US-based pharmaceutical developer and manufacturer, obtained approval from the U.S. Food and Drug Administration (FDA) for Verzenio (abemaciclib) as the first and sole CDK4/6 inhibitor used in combination with endocrine therapy (such as tamoxifen or an aromatase inhibitor). This combination therapy is intended for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence and with a Ki-67 score of 20%. This tailored treatment option represents a significant advancement offering improved outcomes for individuals in need of more effective therapeutic approaches.

In July 2022, Pfizer Inc., a renowned US-based pharmaceutical company specializing in CDK4/6 inhibitor drugs, embarked on a collaboration with Arvinas Inc., a prominent biopharmaceutical company also based in the United States. Their joint objective involves the development and commercialization of ARV-471, an investigative oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. This partnership is geared towards addressing the treatment needs of patients coping with locally advanced or metastatic breast cancer. Pfizer Inc. intends to synergize its expertise in CDK4/6 inhibitor drugs to maximize the therapeutic potential and effectiveness of ARV-471 in treating this challenging medical condition.

Major companies operating in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Dr. Reddy's Laboratories Ltd, Piramal Group, Hanmi Pharm Co. Ltd., Incepta Pharmaceuticals Ltd, Beacon Pharmaceuticals PLC, Bluepharma, Astex Pharmaceuticals, Arvinas Inc , G1 Therapeutics Inc., Carisma Therapeutics Inc., Beta Pharma Inc., Syros Pharmaceuticals Inc., Cyclacel Pharmaceuticals Inc., Onconova Therapeutics Inc., Context Therapeutics Inc., NanoDaru

North America was the largest region in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market in 2023. The regions covered in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cyclin-dependent kinase (CDK) 4/6 inhibitor drug market consists of sales of trilaciclib and ramiven drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cyclin-dependent kinase (CDK) 4/6 inhibitor drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Type: Palbociclib (Ibrance); Ribociclib (Kisqali); Abermaciclib (Verzenio)
• 3) By Patient: Pre-Menopausal; Post-Menopausal; Other Patients
• 3) By End-Users: Hospitals; Clinics; Research Laboratories; Retail Pharmacies
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Bristol Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Characteristics

3. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Trends And Strategies

4. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Size and Growth

• 5.1. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Segmentation

• 6.1. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Palbociclib (Ibrance)
• Ribociclib (Kisqali)
• Abermaciclib (Verzenio)
• 6.2. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Pre-Menopausal
• Post-Menopausal
• Other Patients
• 6.3. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Research Laboratories
• Retail Pharmacies

7. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Regional And Country Analysis

• 7.1. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 8.1. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 9.1. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 9.2. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 10.1. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 11.1. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 11.2. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 12.1. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 13.1. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 14.1. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 14.2. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 15.1. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 15.2. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 16.1. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 17.1. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 18.5. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 19.9. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 20.13. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 21.1. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 21.2. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 22.1. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 23.1. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 23.2. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 24.1. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 24.2. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 25.1. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 25.2. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 26.1. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 26.2. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 27.1. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 28.1. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 28.2. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 29.1. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 29.2. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Landscape And Company Profiles

• 30.1. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Landscape
• 30.2. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck & Co. Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bristol Myers Squibb Company
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AstraZeneca PLC
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. Gilead Sciences, Inc
• 31.4. Incyte Corporation
• 31.5. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• 31.6. Dr. Reddy's Laboratories Ltd
• 31.7. Piramal Group
• 31.8. Hanmi Pharm Co. Ltd.
• 31.9. Incepta Pharmaceuticals Ltd
• 31.10. Beacon Pharmaceuticals PLC
• 31.11. Bluepharma
• 31.12. Astex Pharmaceuticals
• 31.13. Arvinas Inc
• 31.14. G1 Therapeutics Inc.
• 31.15. Carisma Therapeutics Inc.

32. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Benchmarking

33. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

35. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Future Outlook and Potential Analysis

• 35.1 Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer